Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
Related Questions
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
What are some situations where a non-prednisone steroid would be more appropriate than prednisone?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
